Page 7 - Pharma Sector

Mankind Pharma Q3 PAT up 9.5%, revenue rises 11.5% on chronic drugs sales

Mankind Pharma posted a 9.5 per cent rise in Q3FY26 net profit and 11.5 per cent growth in revenue, driven by strong domestic demand for chronic therapies

Budget 2026: Pharma dept prescribes PLI boost for bulk drug output

FY27 PLI scheme allocation rises 2.24%, aiming to add 500 MT to domestic API production

Union Budget 2026-27: Over ₹1 trillion earmarked for the nation's health

Biopharma Shakti initiative to tackle burden of non-communicable diseases, turn India into global, innovation-led hub

Budget 2026: Towards a healthier India through strategic healthcare push

The Budget reframes healthcare as a strategic national capability, backing biopharma innovation, workforce expansion and technology-led governance to power India's next growth phase

Budget 2026: Biopharma Shakti plan aims to make India a biologics hub

Union Budget 2026: Finance Minister Nirmala Sitharaman unveils Biopharma Shakti, a ₹10,000 crore, five-year plan to boost domestic biologics, biosimilars, clinical trials and regulatory capacity

FM announces ₹10,000 crore scheme to promote biopharma manufacturing

Finance Minister Nirmala Sitharaman announced Mission Biopharma Shakti in the Budget, a five-year ₹10,000 crore programme to build domestic capabilities in biologics, biosimilars and clinical research

Centre proposes amendment to allow drug imports via Navi Mumbai airport

Health Ministry proposes listing Navi Mumbai International Airport as a notified port under drug rules, enabling air import of medicines through the facility

Sun Pharma Q3 Preview: Profit, revenue and key factors to watch in Dec qtr

Sun Pharma's net profit is expected to come at ₹3,040 crore, marking a decline of 5.6 per cent Y-o-Y, as against ₹3,220 crore in the year-ago period

India-EU free trade pact set to redraw growth map for Indian CDMOs

India-EU FTA could transform India's CDMO sector by cutting pharma tariffs, easing regulations and deepening Indian integration into Europe's drug supply chains

India-EU FTA: Brokerages decode impact for markets, sectors, companies

In fiscal 2024-25 (FY25), India, according to HSBC, exported $76 billion worth of goods to the EU and bought $61 billion worth of goods from the EU

Centre puts stricter controls on pregabalin sales over abuse concerns

India has moved pregabalin to Schedule H1, tightening prescription and record-keeping norms after states flagged widespread misuse of the nerve pain drug for intoxication

Centre scraps prior approval system for BA/BE studies of low-risk drugs

The health ministry has amended clinical trial rules to replace prior approvals for low-risk BA/BE studies with simple online intimations, a move aimed at cutting delays, easing compliance

Govt eases drug R&D norms, allows pharma firms to skip test licences

Pharma companies will no longer ne required to seek a test licence and may proceed with pharmaceutical development upon submitting an online intimation to CDSCO, except in certain cases, as part of broad simplication notified by the Union Health Ministry. Union Health Ministry has notified key amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019, aimed at simplifying regulatory processes, reducing approval timelines, and enabling faster conduct of clinical research and pharmaceutical development in the country. The amendment is line with the directions of Prime Minister Narendra Modi to reduce regulatory burden and promote Ease of Doing Business, the ministry sais Under the existing regulatory framework, pharmaceutical companies are required to obtain a test licence from the Central Drugs Standard Control Organization (CDSCO) for the manufacture of small quantities of drugs intended for examination, research, or analysis purposes. Through the notified amendments, thi

Cipla Q3 results: Net profit slumps 57% to ₹675 crore on US supply issues

Bets on respiratory product launches and peptides for growth

Q3 Preview: Strong domestic sales set to lift pharma revenues by up to 11%

Strong domestic demand is set to lift pharma revenues by up to 11% in Q3FY26, though pressure from generic Revlimid in the US may limit profit growth

JB Pharma Q3 PAT up 22%, revenue rises 11% on better domestic performance

JB Pharma reports a 22% rise in Q3 FY26 profit as strong growth in domestic and international formulations offsets flat CDMO revenues

Delhi HC restores ban on diabetes FDC drugs; proof of harm not needed

The Delhi High Court reinstated the Centre's 2018 ban on certain diabetes fixed-dose combination drugs, ruling that the law allows action based on potential health risks

IPA members commit $50 million to set up pharma skilling academy PAGE

IPA member firms have committed $50 million to launch PAGE, an industry-led academy to boost pharmaceutical manufacturing skills, quality systems and regulatory compliance in India

Indian CRDMO market to outpace APAC; HDFC Sec starts coverage on top firms

While HDFC Securities has assigned a 'Buy' rating to Divi's Labs, Sai Life Sciences, and Piramal Pharma, it has given an 'Add' rating to Anthem BioSciences and a 'Reduce' rating to Laurus Labs

DoP invites proposals under two schemes to cut medtech import reliance

With India importing about 70 per cent of its medical devices, the Department of Pharmaceuticals has invited proposals under two sub-schemes to reduce import dependence and support clinical studies